FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer
This is the first immunotherapy to be approved for adjuvant use in intermediate- or high-risk patients with renal cell carcinoma after surgery.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hematology | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology